Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 11, 2015, Pages 3032-3041

  Livermore, David M ^a,b   Mushtaq, Shazad ^a   Warner, Marina ^a   Woodford, Neil ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BIAPENEM; CEFEPIME; ERTAPENEM; OP 0595; PIPERACILLIN; UNCLASSIFIED DRUG; AZABICYCLO DERIVATIVE; BETA LACTAM; BETA LACTAMASE; LACTAM; OP0595;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CITROBACTER; CONTROLLED STUDY; DRUG DETERMINATION; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; PSEUDOMONAS AERUGINOSA; SERRATIA; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GREAT BRITAIN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; BETA-LACTAMS; DRUG INTERACTIONS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GREAT BRITAIN; LACTAMS; MICROBIAL SENSITIVITY TESTS;

EID: 84949035632     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv239     Document Type: Article

References (25)

1. Livermore DM, Mushtaq S,Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.
2. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39: 86-9.
3. Morinaka A, Tsutsumi Y, Yamada M et al. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'. J Antimicrob Chemother 2015; 70: 2779-86.
4. Fass RJ. Activity of mecillinam alone and in combination with other β-lactam antibiotics. Antimicrob Agents Chemother 1980; 18: 906-12.
5. Neu HC. Synergy of mecillinam, a ß-amidinopenicillanic acid derivative, combined with β-lactam antibiotics. Antimicrob Agents Chemother 1976; 10: 535-539.
6. Otsuki M. Synergistic effect of cephalexin with mecillinam. J Antibiot (Tokyo) 1981; 34: 739-52.
7. Spratt BG. The mechanism of mecillinam. J Antimicrob Chemother 1977; 3 Suppl B: 13-9.
8. Doumith M, Ellington MJ, Livermore DM et al. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates fromthe UK. J Antimicrob Chemother 2009; 63: 659-67.
9. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A9. Wayne, PA, USA: CLSI; 2011.
10. Chen HY, Livermore DM. Comparative in-vitro activity of biapenem against enterobacteria with β-lactamase-mediated antibiotic resistance. J Antimicrob Chemother 1994; 33: 453-64.
11. Oueslati S, Nordmann P, Poirel L. Heterogeneous hydrolytic features for OXA-48-like β-lactamases. J Antimicrob Chemother 2015; 70: 1059-63.
12. Chen HY, Livermore DM. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J Antimicrob Chemother 1994; 33: 949-58.
13. Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 2013; 68: 2286-90.
14. Zhou XY, Kitzis MD, Gutmann L. Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 1387-9.
15. Livermore DM, Chen HY. Potentiation of β-lactams against Pseudomonas aeruginosa by Ro 48-1256, a bridged monobactam inhibitor of AmpC β-lactamases. J Antimicrob Chemother 1997; 40: 335-43.
16. Neu HC. Mecillinam, a novel penicillanic acid derivative with unusual activity against Gram-negative bacteria. Antimicrob Agents Chemother 1976; 9: 793-9.
17. Legaree BA, Daniels K, Weadge JT et al. Function of penicillin-binding protein 2 in viability and morphology of Pseudomonas aeruginosa. J Antimicrob Chemother. 2007; 59: 411-24.
18. Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J Antimicrob Chemother 1995; 35: 75-84.
19. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem 2013; 288: 27960-71.
20. Varma A, Young KD. In Escherichia coli, MreB and FtsZ direct the synthesis of lateral cell wall via independent pathways that require PBP 2. J Bacteriol 2009; 191: 3526-33.
21. Vinella D, Cashel M, D'Ari R. Selected amplification of the cell division genes ftsQ-ftsA-ftsZ in Escherichia coli. Genetics 2000; 156: 1483-92.
22. Young KD. Why spherical Escherichia coli dies: the inside story. J Bacteriol 2008; 190: 1497-8.
23. Thulin E, Sundqvist M, Andersson DI. Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli. Antimicrob Agents Chemother 2015; 59: 1718-27.
24. Wang X, Zhang F, Zhao C et al. In vitro activities of ceftazidimeavibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014; 58: 1774-8.
25. Livermore DM, Warner M, Jamrozy D et al. In-vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015; pii: AAC.00678-15.